Ernexa Therapeutics (ERNAW) Free Cash Flow (2010 - 2026)

Ernexa Therapeutics has reported Free Cash Flow for 17 years, with the latest figure at -$2.3 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow fell 11.48% year-over-year to -$2.3 million; the trailing twelve-month figure through Mar 2026 stood at -$7.3 million (up 49.6% YoY), and the FY2025 full-year result was -$7.1 million, up 56.47% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$2.3 million, down from -$1.2 million in the prior quarter.
• The five-year high for Free Cash Flow was -$1.2 million in Q4 2025, with the low at -$6.3 million in Q3 2024.
• Historically, Free Cash Flow has averaged -$4.0 million across 5 years, with a median of -$3.9 million in 2023.
• Annual changes were most pronounced in 2022 — Free Cash Flow tumbled 134.38% — and 2025, when it surged 79.87%.
• Ernexa Therapeutics' Free Cash Flow stood at -$5.5 million in 2022, then increased by 14.22% to -$4.7 million in 2023, then gained by 24.25% to -$3.5 million in 2024, then soared by 67.19% to -$1.2 million in 2025, then sank by 97.94% to -$2.3 million in 2026.
• The last three Free Cash Flow figures came in at -$2.3 million (Q1 2026), -$1.2 million (Q4 2025), and -$1.3 million (Q3 2025), per Business Quant data.